Viewing Study NCT02051218

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:53 AM
Ignite Modification Date: 2026-02-25 @ 10:13 PM
Study NCT ID: NCT02051218
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-03-13
First Post: 2014-01-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Sponsor: Swiss Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None Metastatic Prostate Cancer View
None Bone Metastases View
Keywords:

Keywords

Keyword Brief Keyword Text View
None metastatic breast cancer View
None castration resistant metastatic prostate cancer View
None bone metastases View
None Denosumab View
None XGEVA View
None de-escalation View